Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology
Open accessThe DOI matches its Crossref record; 273 of the 273 references it cites were found in a registry or an index.
Abstract
These British Association for Psychopharmacology guidelines cover the range and aims of treatment for anxiety disorders. They are based explicitly on the available evidence and are presented as recommendations to aid clinical decision making in primary and secondary medical care. They may also serve as a source of information for patients and their carers. The recommendations are presented together with a more detailed review of the available evidence. A consensus meeting involving experts in anxiety disorders reviewed the main subject areas and considered the strength of evidence and its clinical implications. The guidelines were constructed after extensive feedback from participants and interested parties. The strength of supporting evidence for recommendations was rated. The guidelines cover the diagnosis of anxiety disorders and key steps in clinical management, including acute treatment, relapse prevention and approaches for patients who do not respond to first-line treatments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is in line with the clinical observation that specific phobias respond less well to treatments such as citalopram than other pathological anxiety states (Baldwin et al, 2005) and with preclinical evidence in rodents showing that the serotonergic system may not be critical for the expression of phasic fear-potentiated startle (Davis et al, 1988).”
From Phasic vs Sustained Fear in Rats and Humans: Role of the Extended Amygdala in Fear vs Anxiety (2010) · cites this paper as Baldwin et al, 2005
Citations
Cites
1 retracted
Items 201–273 of 273
Kampman, M., Keijsers, G. P. J., Hoogduin, C. A. L., & Hendriks, G.-J. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0904 · Cited by 87
Sexual dysfunction associated with antidepressant drugs
Baldwin, D. S. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.5.457 · Cited by 84
Self-citationCognitive therapy vs behaviour therapy in the treatment of chronic general anxiety
Durham, R. C., & Turvey, A. A. (1987) · Behaviour Research and Therapy · doi:10.1016/0005-7967(87)90051-9 · Cited by 84
Death and Dependence: Current Controversies over the Selective Serotonin Reuptake Inhibitors
Nutt, D. J. (2003) · Journal of Psychopharmacology · doi:10.1177/0269881103174019 · Cited by 84
Self-citationWittchen, H.-U., & Boyer, P. (1998) · British Journal of Psychiatry · doi:10.1192/s000712500029346x · Cited by 82
Serotonin Reuptake Inhibitor Discontinuation Syndrome: A Hypothetical Definition
Schatzberg, A. F., Haddad, P. M., Kaplan, E. M., Lejoyeux, M., Rosenbaum, J. F., Young, A. H., & Zajecka, J. (1997) · The Journal of Clinical Psychiatry · Cited by 82
MUNJACK, D. J., CROCKER, B., CABE, D., BROWN, R., USIGLI, R., ZULUETA, A., MCMANUS, M., MCDOWELL, D., PALMER, R., & LEONARD, M. (1989) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198902000-00005 · Cited by 81
GABA-Ergic Drugs: Exit Stage Left, Enter Stage Right
Ashton, H., & Young, A. H. (2003) · Journal of Psychopharmacology · doi:10.1177/0269881103017002004 · Cited by 81
Otto, M., Pollack, M., Penava, S. J., & Zucker, B. G. (1999) · Behaviour Research and Therapy · doi:10.1016/s0005-7967(98)00176-4 · Cited by 80
PIGOTT, T. A., L??HEUREUX, F., HILL, J. L., BIHARI, K., BERNSTEIN, S. E., & MURPHY, D. L. (1992) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199202000-00003 · Cited by 80
The evidence-based pharmacological treatment of social anxiety disorder
Blanco, C., Raza, M. S., Schneier, F. R., & Liebowitz, M. R. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003791 · Cited by 79
Sertraline treatment of panic disorder: results of a long-term study
Rapaport, M. H., Wolkow, R., Rubin, A., Hackett, E., Pollack, M., & Ota, K. Y. (2001) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2001.00263.x · Cited by 79
Husted, D. S., & Shapira, N. A. (2004) · CNS Spectrums · doi:10.1017/s109285290000225x · Cited by 79
Power, K., Simpson, R., Swanson, V., & Wallace, L. A. (1990) · Europe PMC (PubMed Central) · Cited by 77
Davis, L. L., Jewell, M. E., Ambrose, S., Farley, J., English, B., Bartolucci, A., & Petty, F. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000125685.82219.1a · Cited by 73
Montgomery, S., Sheehan, D. V., Meoni, P., Haudiquet, V., & Hackett, D. (2002) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(02)00005-5 · Cited by 71
Treatment of anxiety and depressive disorders in patients with cardiovascular disease
Davies, S. J. C., Jackson, P. R., Potokar, J., & Nutt, D. J. (2004) · BMJ · doi:10.1136/bmj.328.7445.939 · Cited by 70
Self-citationDouble-blind placebo-controlled pilot study of paroxetine for specific phobia
Benjamin, J., Ben-Zion, I. Z., Karbofsky, E., & Dannon, P. N. (2000) · Psychopharmacology · doi:10.1007/s002130000372 · Cited by 68
Cottraux, J., Note, I.-D., Cungi, C., Légeron, P., Heim, F., Chneiweiss, L., Bernard, G., & Bouvard, M. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.167.5.635 · Cited by 67
Huppert, J. D., Schultz, L. T., Foa, E. B., Barlow, D. H., Davidson, J. R. T., Gorman, J. M., Shear, M. K., Simpson, H. B., & Woods, S. W. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1485 · Cited by 67
Self-citationEfficacy of self-help manuals for anxiety disorders in primary care: a systematic review
van Boeijen, C. A. (2005) · Family Practice · doi:10.1093/fampra/cmh708 · Cited by 65
Tiagabine for Posttraumatic Stress Disorder: A Case Series of 7 Women
Taylor, F. B. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1204 · Cited by 61
Mundo, E., Guglielmo, E., & Bellodi, L. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199809000-00005 · Cited by 59
MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine
van Vliet, I. M., Westenberg, H. G. M., & den Boer, J. A. (1993) · Psychopharmacology · doi:10.1007/bf02244898 · Cited by 59
Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.
Tollefson, G. D., Birkett, M. A., Koran, L. M., & Genduso, L. A. (1994) · PubMed · Cited by 57
Martinsen, E. W., Olsen, T., Tonset, E., Nyland, K. E., & Aarre, T. F. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0808 · Cited by 57
Blier, P., & Bergeron, R. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199603000-00005 · Cited by 57
Moclobemide and fluoxetine for panic disorder
Tiller, J. W. G., Bouwer, C., Behnke, K., & For the International Panic Disorder Study Group (1999) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/pl00014164 · Cited by 56
Uhlenhuth, E. H., Balter, M. B., Ban, T. A., & Yang, K. (1999) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1999)9:3<107::aid-da2>3.0.co;2-t · Cited by 56
WCA Recommendations for the Long-Term Treatment of Panic Disorder
Pollack, M. H., Allgulander, C., Bandelow, B., Cassano, G. B., Greist, J. H., Hollander, E., Nutt, D. J., Okasha, A., & Swinson, R. P. (2003) · CNS Spectrums · doi:10.1017/s109285290000691x · Cited by 55
Self-citationAn empirical approach to subtype identification in individuals with social phobia
ENG, W., HEIMBERG, R. G., COLES, M. E., SCHNEIER, F. R., & LIEBOWITZ, M. R. (2000) · Psychological Medicine · doi:10.1017/s0033291799002895 · Cited by 55
(1952) · International Journal of Legal Medicine · doi:10.1007/bf00665253 · Cited by 55
Davidson, J. R. T., Connor, K. M., Hertzberg, M. A., Weisler, R. H., Wilson, W. H., & Payne, V. M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000155817.21467.6c · Cited by 54
Self-citationMichelson, D., Pollack, M., Lydiard, R. B., Tamura, R., Tepner, R., Tollefson, G., & The Fluoxetine Panic Disorder Study Group (1999) · British Journal of Psychiatry · doi:10.1192/bjp.174.3.213 · Cited by 54
Randomized, placebo-controlled trial
Abdukareem, A. A. (2004) · Annals of Saudi Medicine · doi:10.5144/0256-4947.2004.145 · Cited by 54
The relative efficacy of buspirone, imipramine and placebo in panic disorder: A preliminary report
Sheenan, D. V., Raj, A. B., Sheehan, K. H., & Soto, S. (1988) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(88)90214-6 · Cited by 51
Stein, M. B., Norton, G. R., Walker, J. R., Chartier, M., & Graham, R. M. (2000) · Psychiatry Research · doi:10.1016/s0165-1781(00)00154-2 · Cited by 51
Paroxetine in the treatment of panic disorder
Judge, R., Öhrström, J. K., Manniche, P. M., Christiansen, P. E., Øhrberg, S., Behnke, K., Borup, A., Severin, B., Søgaard, J., & Calberg, H. (1993) · European Neuropsychopharmacology · doi:10.1016/0924-977x(93)90163-g · Cited by 50
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.9.1293 · Cited by 49
Bertani, A., Perna, G., Migliarese, G., Di Pasquale, D., Cucchi, M., Caldirola, D., & Bellodi, L. (2004) · Pharmacopsychiatry · doi:10.1055/s-2004-832593 · Cited by 49 · cited 1×
“, 2003), and some SSRIs (paroxetine, fluvoxamine) to some noradrenaline reuptake inhibitors (reboxetine, maprotiline) (Ib) (Den Boer et al., 1988; Bertani et al., 2004).”
BackgroundLong-term Maintenance and Discontinuation of Imipramine Therapy in Panic Disorder With Agoraphobia
Mavissakalian, M. R., & Perel, J. M. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.9.821 · Cited by 48
WCA Recommendations for the Long-Term Treatment of Social Phobia
Van Ameringen, M., Allgulander, C., Bandelow, B., Greist, J. H., Hollander, E., Montgomery, S. A., Nutt, D. J., Okasha, A., Pollack, M. H., Stein, D. J., et al. (2003) · CNS Spectrums · doi:10.1017/s1092852900006933 · Cited by 48
Self-citationDowell, A. C., & Biran, L. A. (1990) · Europe PMC (PubMed Central) · Cited by 47
Stein, D. J., Westenberg, H. G. M., Yang, H., Li, D., & Barbato, L. M. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570300364x · Cited by 47
Effective short-term treatment of generalized anxiety disorder with trifluoperazine.
MENDELS, J., Krajewski, T. F., Huffer, V., Taylor, R. J., Secunda, S. K., Schless, A. P., Sebastian, J. A., Semchyshyn, G., Mj, D., & As, M. (1986) · PubMed · Cited by 47
Screening for anxiety and depression in primary care with the Duke Anxiety-Depression Scale.
Parkerson, G. R., & Broadhead, W. E. (1997) · PubMed · Cited by 47
Cognitive Behavior Therapy in Panic Disorder and Comorbid Major Depression
Rief, W., Trenkamp, S., Auer, C., & Fichter, M. M. (2000) · Psychotherapy and Psychosomatics · doi:10.1159/000012369 · Cited by 44
Frommberger, U., Stieglitz, R.-D., Nyberg, E., Richter, H., Novelli-Fischer, U., Angenendt, J., Zaninelli, R., & Berger, M. (2004) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500310004803 · Cited by 42
Death by tricyclic: the real antidepressant scandal?
Nutt, D. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105051987 · Cited by 39
Self-citationPharmacotherapy of panic disorder: differential efficacy from a clinical viewpoint.
den Boer, J. A. (1998) · PubMed · Cited by 39
El-Khayat, R., & Baldwin, D. S. (1998) · Journal of Psychopharmacology · doi:10.1177/026988119801200401 · Cited by 39
Self-citationPsychotherapy in the overall management strategy for social anxiety disorder.
Baldwin, D. S., & Birtwistle, J. (1998) · PubMed · Cited by 39
Self-citationInteraction of pharmacological and psychological treatments of anxiety
Lader, M. H., & Bond, A. J. (1998) · British Journal of Psychiatry · doi:10.1192/s0007125000293513 · Cited by 38
Self-citationThree year naturalistic outcome study of panic disorder patients treated with paroxetine
Dannon, P. N., Iancu, I., Cohen, A., Lowengrub, K., Grunhaus, L., & Kotler, M. (2004) · BMC Psychiatry · doi:10.1186/1471-244x-4-16 · Cited by 38
Meibach, R. C., Dunner, D., Wilson, L. G., Ishiki, D., & Dager, S. R. (1987) · PubMed · Cited by 38
Dannon, P. N., Iancu, I., & Grunhaus, L. (2002) · Depression and Anxiety · doi:10.1002/da.10063 · Cited by 36
The development of agoraphobia in panic disorder: a predictable process?
Langs, G., Quehenberger, F., Fabisch, K., Klug, G., Fabisch, H., & Zapotoczky, H. G. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00097-x · Cited by 35
Meoni, P., Hackett, D., & LADER, M. H. (2004) · Depression and Anxiety · doi:10.1002/da.10141 · Cited by 32
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.12.1878 · Cited by 29
Long-term course and outcome in panic disorder: A naturalistic follow-up study
Cowley, D. S., Flick, S. N., & Roy-Byrne, P. P. (1996) · Anxiety · doi:10.1002/(sici)1522-7154(1996)2:1<13::aid-anxi2>3.0.co;2-e · Cited by 29
Anxiety sensitivity and treatment outcome in panic disorder
Hazen, A. L., Walker, J. R., & Eldridge, G. D. (1996) · Anxiety · doi:10.1002/(sici)1522-7154(1996)2:1<34::aid-anxi5>3.0.co;2-d · Cited by 28
Embarrassment about the first panic attack predicts agoraphobia in panic disorder patients
Amering, M., Katschnig, H., Berger, P., Windhaber, J., Baischer, W., & Dantendorfer, K. (1997) · Behaviour Research and Therapy · doi:10.1016/s0005-7967(96)00126-x · Cited by 25
The placebo response in social phobia
Oosterbaan, D. B., van Balkom, A. J. L. M., Spinhoven, P., & van Dyck, R. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500314 · Cited by 22
Social phobia in general health care
Weiller, E., Amorin, P., Boyer, P., Lépine, J., & Lecrubier, Y. (1994) · European Neuropsychopharmacology · doi:10.1016/0924-977x(94)90027-2 · Cited by 21
Neurosurgery for mental disorder
Christmas, D. M. B., Matthews, K., & Eljamel, S. (2004) · The British Journal of Psychiatry · doi:10.1192/bjp.185.2.173-a · Cited by 21
Adinazolam, Diazepam, Imipramine, and Placebo in Major Depressive Disorder: A Controlled Study*
Rickels, K., London, J., Fox, I., Hassman, H. H., Csanalosi, I., & Weise, C. (1991) · Pharmacopsychiatry · doi:10.1055/s-2007-1014455 · Cited by 18
Nease, D. E., & Aikens, J. E. (2003) · BMJ · doi:10.1136/bmj.327.7422.1030 · Cited by 18
Guest, J. F., Russ, J., & Lenox‐Smith, A. (2005) · The European Journal of Health Economics · doi:10.1007/s10198-004-0272-z · Cited by 17
Baldwin, D. S., Huusom, A. K. T., & Mæhlum, E. (2004) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(04)80399-7 · Cited by 9
Self-citation[Generalized anxiety disorders in primary medical care].
Hoyer, J., & Wïttchen, H. (2003) · PubMed · Cited by 5
Fineberg, N. A., Heyman, I., Jenkins, R., Premkumar, P., Veale, D. M., Kendall, T., & Freeston, M. H. (2004) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(04)80133-0 · Cited by 4
Self-citation(1998) · doi:10.1002/(sici)1099-0879(199809)5:3
Lorberbaum (1999) · doi:10.1002/(sici)1520-6394(1999)10:3
Research works printed but not linked: 39
- Allgulander C, ADAA meeting
- Baldwin D S, 1998, J Clin Psychiatry, 59, S39
- Ballenger J C, 1998, J Clin Psychiatry, 59, 47
- Ballenger J C, 1998, J Clin Psychiatry, 59, 54
- Ballenger J C, 2001, J Clin Psychiatry, 62, 53
- Ballenger J C, 2004, J Clin Psychiatry, 65, 55
- Bielski R J, 42nd Annual Meeting of the American College of Neuropsychopharmacology
- Bower P, 2001, Br J Gen Pract, 51, 838
- Committee on Safety of Medicines, 2004, Safety of selective serotonin reuptake inhibitor antidepressants
- Davidson J R, American College of Neuropsychopharmacology
- Den Boer J A, 1998, J Clin Psychiatry, 59, 30
- Dowell A C, 1990, Br J Gen Pract, 40, 27
- Durham R C, Long-term outcome of cognitive behavior therapy clinical trials in central Scotland
- Friedman M J, 2000, Effective Treatments for PTSD: Practice Guidelines from the International Society for Stress Studies, 84
- Gelpin E, 1996, J Clin Psychiatry, 57, 390
- Goldberg D, 1987, J R Coll Gen Pract, 37, 15
- Jorm A F, 2004, Med J Aust, 181, S29
- 10.1037/0022-006x.62.4.865 · DOI · Paper page
- 10.1002/(sici)1520-6394(1999)10:3<89::aid-da1>3.0.co;2-5 · doi:10.1002/(sici)1520-6394(1999)10:3<89::aid-da1>3.0.co;2-5
- Meibach R C, 1987, J Clin Psychiatry, 84, 355
- Mendels J, 1986, J Clin Psychiatry, 47, 170
- National Institute for Clinical Excellence, 2004, Depression. Management of depression in primary and secondary care
- National Institute for Clinical Excellence, 2005, Post-traumatic stress disorder. The management of PTSD in adults and children in primary and secondary care
- Parkerson G R Jr, 1997, Fam Med, 29, 177
- Pollack M H, American College of Neuropsychopharmacology
- Pollack M H, 1994, J Clin Psychiatry, 55, 200
- Power K G, 1990, Br J Gen Pract, 40, 289
- Rasmussen S A, 1990, J Clin Psychiatry, 51, 10
- Royal College of Psychiatrists, 2005, Benzodiazepines: risks, benefits or dependence. A re-evaluation
- Sasson Y, 1997, J Clin Psychiatry, 58, 7
- Schatzberg A F, 1997, J Clin Psychiatry, 58, 5
- Stein D J, 2004, Cochrane Library
- Tollefson G D, 1994, J Clin Psychiatry, 55, 69
- 10.1002/(sici)1099-0879(199809)5:3<126::aid-cpp153>3.0.co;2-h · doi:10.1002/(sici)1099-0879(199809)5:3<126::aid-cpp153>3.0.co;2-h
- Weissman M M, 1994, J Clin Psychiatry, 55, 5
- Wheadon D, Annual Meeting of the American College of Neuro psychopharmacology
- Wittchen H U, 2002, J Clin Psychiatry, 63, 24
- World Health Organization, 1992, The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines
- World Health Organization, 2004, WHO Guide to Mental and Neurological Health in Primary Care
Cited by
Phasic vs Sustained Fear in Rats and Humans: Role of the Extended Amygdala in Fear vs Anxiety
Davis, M., Walker, D. L., Miles, L., & Grillon, C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.109 · Cited by 1,513
Comorbidity of anxiety and depression in children and adolescents: 20 years after
Cummings, C. M., Caporino, N. E., & Kendall, P. C. (2014) · Psychological Bulletin · doi:10.1037/a0034733 · Cited by 1,028
“SSRIs are frequently prescribed for child/adolescent anxiety disorders (Baldwin et al., 2005) and depression (Birmaher & Brent, 2002).”
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Self-citationBandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Self-citationInternet Addiction: Definition, Assessment, Epidemiology and??Clinical Management
Shaw, M., & Black, D. W. (2008) · CNS Drugs · doi:10.2165/00023210-200822050-00001 · Cited by 807
Metadata
- Authors
- Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., & Wittchen, H. U.
- Affiliations
- University of Southampton (GB)
- University of Manchester (GB)
- University of Bristol (GB)
- University of Göttingen (DE)
- King's College London (GB)
- Duke Medical Center (US)
- School of Behavioral and Cognitive Neurosciences, University Medical Center Groningen, Groningen, the Netherlands
- University of Hertfordshire (GB)
- Technical University of Dresden and Max Planck Institute of Psychiatry, Munich, Germany
- Corresponding author
- Baldwin, David S.
- ORCID
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2005-11
- Volume
- 19
- Issue
- 6
- Pages
- 567-596
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2151852296
- Cited by
- 617
- References
- 273
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 13 · 2023: 6 · 2022: 9 · 2021: 21 · 2020: 22 · 2019: 22 · 2018: 26 · 2017: 24 · 2016: 22 · 2015: 29 · 2014: 53 · 2013: 47 · 2012: 53
- FWCI
- 45.54
- Type
- journal article
- Language
- en
- Open access
- green
- tud.qucosa.de
- Licence
- other-oa
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Max Planck Institute for Plasma Physics (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Qucosa (Saxon State and University Library Dresden) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- anxiety disorders, pharmacotherapy, psychopharmacology, treatment guidelines, evidence-based recommendations, acute treatment, relapse prevention, treatment-resistant anxiety, clinical decision-making
- MeSH terms
- Adolescent, Adult, Aged, Antidepressive Agents, Anxiety Disorders, Behavior Therapy, Breast Feeding, Child, Preschool, Combined Modality Therapy, Female, Humans, Male, Middle Aged, Pregnancy, Psychotropic Drugs, Anti-Anxiety Agents, Treatment Outcome, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.